The Program has been a major focus of the SPORE because it provides for a continuous flow of innovative ideas and activity to stimulate investigation in the context of SPORE translational research. The Developmental Research Program provides a means to respond to new opportunities, and is designed to encourage and facilitate new research efforts. The Program takes advantage of the broad expertise of researchers at The Johns Hopkins University and of external investigators by providing funds for pilot projects with potential for development into full-fledged translational research avenues, collaborations, and new methodologies for integration into other Research Projects. In most prior years, the Cancer Center has augmented the funding provided to each of our pilot project recipients by approximately 50% per award (on average). In the past two years, the formation of a GI Cancer program within the Oncology Center has also provided support for additional basic and clinical pilot projects that are not intended to be as translational as the goals of the SPORE Developmental Projects. Within this year, we also have gained a commitment for an additional two pancreatic cancer pilot projects to be funded by institutional sources each year. These resources, and funding pressures from a reduced overall budget for the proposed SPORE funding period, have allowed us to shift some of the financial sources from the SPORE to the institution, as reflected in the newly proposed Developmental Research Budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-19
Application #
8366127
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
1997-02-28
Project End
2017-08-31
Budget Start
2012-09-19
Budget End
2013-08-31
Support Year
19
Fiscal Year
2012
Total Cost
$130,248
Indirect Cost
$49,849
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205
Chu, Nam; Salguero, Antonieta L; Liu, Albert Z et al. (2018) Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. Cell 174:897-907.e14
Felsenstein, Matthäus; Noë, Michaël; Masica, David L et al. (2018) IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut 67:1652-1662
Grant, Robert C; Denroche, Robert E; Borgida, Ayelet et al. (2018) Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology 154:719-722.e3
Tie, Jeanne; Cohen, Joshua D; Wang, Yuxuan et al. (2018) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut :
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Ma, Qianqian; Gabelli, Sandra B; Raben, Daniel M (2018) Diacylglycerol kinases: Relationship to other lipid kinases. Adv Biol Regul :

Showing the most recent 10 out of 883 publications